Pure Bioscience, Inc. (PURE) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-14.37M
Share-based compensation	1.9M
Amortization of stock issued for services	225K
Depreciation and amortization
Accounts receivable	-74K
Inventories	-143K
Prepaid expenses	-8K
Accounts payable and accrued liabilities	-131K
Deferred revenue
Deferred rent	-6K
Net cash used in operating activities	-4.99M
Investment in patents	-15K
Purchases of property, plant and equipment	-390K
Net cash used in investing activities	-405K
Net proceeds from the sale of common stock
Net proceeds from exercise of stock options and warrants
Net cash provided by financing activities	9.27M
Net decrease in cash and cash equivalents	3.87M
Cash and cash equivalents at beginning of period	1.32M
Cash and cash equivalents at end of period	5.19M
Cash paid for taxes
Common stock issued for prepaid services
Common stock issued under stock purchase agreement

Entities mentioned with PURE

View All Entities